Literature DB >> 20440378

Accelerator mass spectrometry-enabled studies: current status and future prospects.

Ali Arjomand1.   

Abstract

Accelerator mass spectrometry is a detection platform with exceptional sensitivity compared with other bioanalytical platforms. Accelerator mass spectrometry (AMS) is widely used in archeology for radiocarbon dating applications. Early exploration of the biological and pharmaceutical applications of AMS began in the early 1990s. AMS has since demonstrated unique problem-solving ability in nutrition science, toxicology and pharmacology. AMS has also enabled the development of new applications, such as Phase 0 microdosing. Recent development of AMS-enabled applications has transformed this novelty research instrument to a valuable tool within the pharmaceutical industry. Although there is now greater awareness of AMS technology, recognition and appreciation of the range of AMS-enabled applications is still lacking, including study-design strategies. This review aims to provide further insight into the wide range of AMS-enabled applications. Examples of studies conducted over the past two decades will be presented, as well as prospects for the future of AMS.

Entities:  

Mesh:

Year:  2010        PMID: 20440378      PMCID: PMC2861834          DOI: 10.4155/bio.09.188

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  147 in total

Review 1.  Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research.

Authors:  K W Turteltaub; J S Vogel
Journal:  Curr Pharm Des       Date:  2000-07       Impact factor: 3.116

2.  Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.

Authors:  Xiao-Jian Zhou; R Colin Garner; Sheila Nicholson; C James Kissling; Douglas Mayers
Journal:  J Clin Pharmacol       Date:  2009-09-23       Impact factor: 3.126

3.  A new method for carbon isotopic analysis of protein.

Authors:  D E Nelson
Journal:  Science       Date:  1991-02-01       Impact factor: 47.728

4.  Comparative biotransformation studies of MeIQx and PhIP in animal models and humans.

Authors:  R C Garner; T J Lightfoot; B C Cupid; D Russell; J M Coxhead; W Kutschera; A Priller; W Rom; P Steier; D J Alexander; S H Leveson; K H Dingley; R J Mauthe; K W Turteltaub
Journal:  Cancer Lett       Date:  1999-09-01       Impact factor: 8.679

Review 5.  Applications of accelerator mass spectrometry for pharmacological and toxicological research.

Authors:  Karen Brown; Elaine M Tompkins; Ian N H White
Journal:  Mass Spectrom Rev       Date:  2006 Jan-Feb       Impact factor: 10.946

6.  Kinetic modeling of folate metabolism through use of chronic administration of deuterium-labeled folic acid in men.

Authors:  T E Stites; L B Bailey; K C Scott; J P Toth; W P Fisher; J F Gregory
Journal:  Am J Clin Nutr       Date:  1997-01       Impact factor: 7.045

Review 7.  Neuroscience and accelerator mass spectrometry.

Authors:  Magnus Palmblad; Bruce A Buchholz; Darren J Hillegonds; John S Vogel
Journal:  J Mass Spectrom       Date:  2005-02       Impact factor: 1.982

8.  Binding of nitrobenzene to hepatic DNA and hemoglobin at low doses in mice.

Authors:  Hongli Li; Haifang Wang; Hongfang Sun; Yuanfang Liu; Kexin Liu; Shixiang Peng
Journal:  Toxicol Lett       Date:  2003-03-20       Impact factor: 4.372

9.  Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.

Authors:  Yoshihiro Miyaji; Tomoko Ishizuka; Kenji Kawai; Yoshimi Hamabe; Teiji Miyaoka; Toshinari Oh-hara; Toshihiko Ikeda; Atsushi Kurihara
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

10.  Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

Authors:  J H Beumer; R C Garner; M B Cohen; S Galbraith; G F Duncan; T Griffin; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2007-03-09       Impact factor: 3.850

View more
  4 in total

Review 1.  Quantifying exploratory low dose compounds in humans with AMS.

Authors:  Stephen R Dueker; Le T Vuong; Peter N Lohstroh; Jason A Giacomo; John S Vogel
Journal:  Adv Drug Deliv Rev       Date:  2010-10-31       Impact factor: 15.470

2.  Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach.

Authors:  Stephen Flach; Marie Croft; Jie Ding; Ron Budhram; Todd Pankratz; Mike Pennick; Graeme Scarfe; Steven Troy; Jay Getsy
Journal:  Drug Des Devel Ther       Date:  2016-09-27       Impact factor: 4.162

Review 3.  Opportunities in low-level radiocarbon microtracing: applications and new technology.

Authors:  Le Thuy Vuong; Qi Song; Hee Joo Lee; Ad F Roffel; Seok-Ho Shin; Young G Shin; Stephen R Dueker
Journal:  Future Sci OA       Date:  2015-12-23

4.  Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data.

Authors:  Christine Huynh; Swen Seeland; Jerome Segrestaa; Carmela Gnerre; Jens Hogeback; Henriette E Meyer Zu Schwabedissen; Jasper Dingemanse; Patricia N Sidharta
Journal:  Front Pharmacol       Date:  2022-03-30       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.